These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

300 related items for PubMed ID: 31990207

  • 1. Successfully treated patients with vortioxetine versus venlafaxine: a simplified cost-effectiveness analysis based on a head-to-head study in Asian patients with major depressive disorder.
    Wang G, Zhao K, Reynaud-Mougin C, Loft H, Ren H, Eriksen HF, Ettrup A.
    Curr Med Res Opin; 2020 May; 36(5):875-882. PubMed ID: 31990207
    [Abstract] [Full Text] [Related]

  • 2. Cost per successfully treated patient for vortioxetine versus duloxetine in adults with major depressive disorder: an analysis of the complete symptoms of depression and functional outcome.
    Christensen MC, Munro V.
    Curr Med Res Opin; 2018 Apr; 34(4):593-600. PubMed ID: 29235884
    [Abstract] [Full Text] [Related]

  • 3. Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study.
    Wang G, Gislum M, Filippov G, Montgomery S.
    Curr Med Res Opin; 2015 Apr; 31(4):785-94. PubMed ID: 25650503
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of vortioxetine versus venlafaxine (extended release) in the treatment of major depressive disorder in South Korea.
    Choi SE, Brignone M, Cho SJ, Jeon HJ, Jung R, Campbell R, Francois C, Milea D.
    Expert Rev Pharmacoecon Outcomes Res; 2016 Oct; 16(5):629-638. PubMed ID: 26641142
    [Abstract] [Full Text] [Related]

  • 5. Vortioxetine for major depressive disorder: An indirect comparison with duloxetine, escitalopram, levomilnacipran, sertraline, venlafaxine, and vilazodone, using number needed to treat, number needed to harm, and likelihood to be helped or harmed.
    Citrome L.
    J Affect Disord; 2016 May 15; 196():225-33. PubMed ID: 26938965
    [Abstract] [Full Text] [Related]

  • 6. Cost-utility analysis of vortioxetine versus agomelatine, bupropion SR, sertraline and venlafaxine XR after treatment switch in major depressive disorder in Finland.
    Soini E, Hallinen T, Brignone M, Campbell R, Diamand F, Cure S, Aalto-Setälä M, Danchenko N, Koponen H, Kolasa K.
    Expert Rev Pharmacoecon Outcomes Res; 2017 Jun 15; 17(3):293-302. PubMed ID: 27680105
    [Abstract] [Full Text] [Related]

  • 7. Relative efficacy and tolerability of vortioxetine versus selected antidepressants by indirect comparisons of similar clinical studies.
    Llorca PM, Lançon C, Brignone M, Rive B, Salah S, Ereshefsky L, Francois C.
    Curr Med Res Opin; 2014 Dec 15; 30(12):2589-606. PubMed ID: 25249164
    [Abstract] [Full Text] [Related]

  • 8. The Clinical and Cost Effectiveness of Vortioxetine for the Treatment of a Major Depressive Episode in Patients With Failed Prior Antidepressant Therapy: A Critique of the Evidence.
    Lomas J, Llewellyn A, Soares M, Simmonds M, Wright K, Eastwood A, Palmer S.
    Pharmacoeconomics; 2016 Sep 15; 34(9):901-12. PubMed ID: 27289476
    [Abstract] [Full Text] [Related]

  • 9. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.
    Wade AG, Fernández JL, François C, Hansen K, Danchenko N, Despiegel N.
    Pharmacoeconomics; 2008 Sep 15; 26(11):969-81. PubMed ID: 18850765
    [Abstract] [Full Text] [Related]

  • 10. Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis.
    Kishi T, Ikuta T, Sakuma K, Okuya M, Hatano M, Matsuda Y, Iwata N.
    Mol Psychiatry; 2023 Jan 15; 28(1):402-409. PubMed ID: 36253442
    [Abstract] [Full Text] [Related]

  • 11. Vortioxetine in patients with major depressive disorder and high levels of anxiety symptoms: An updated analysis of efficacy and tolerability.
    Adair M, Christensen MC, Florea I, Loft H, Fagiolini A.
    J Affect Disord; 2023 May 01; 328():345-354. PubMed ID: 36708956
    [Abstract] [Full Text] [Related]

  • 12. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.
    Jain R, Mahableshwarkar AR, Jacobsen PL, Chen Y, Thase ME.
    Int J Neuropsychopharmacol; 2013 Mar 01; 16(2):313-21. PubMed ID: 22963932
    [Abstract] [Full Text] [Related]

  • 13. The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies.
    Baldwin DS, Chrones L, Florea I, Nielsen R, Nomikos GG, Palo W, Reines E.
    J Psychopharmacol; 2016 Mar 01; 30(3):242-52. PubMed ID: 26864543
    [Abstract] [Full Text] [Related]

  • 14. Effectiveness of vortioxetine in patients with major depressive disorder comorbid with generalized anxiety disorder: Results of the RECONNECT study.
    Christensen MC, Schmidt S, Grande I.
    J Psychopharmacol; 2022 May 01; 36(5):566-577. PubMed ID: 35499104
    [Abstract] [Full Text] [Related]

  • 15. Vortioxetine versus Duloxetine in the Treatment of Patients with Major Depressive Disorder: A Meta-Analysis of Randomized Controlled Trials.
    Li G, Wang X, Ma D.
    Clin Drug Investig; 2016 Jul 01; 36(7):509-17. PubMed ID: 27067232
    [Abstract] [Full Text] [Related]

  • 16. The efficacy and safety of 10 mg/day vortioxetine compared to placebo for adult major depressive disorder: a meta-analysis.
    Zheng J, Wang Z, Li E.
    Afr Health Sci; 2019 Mar 01; 19(1):1716-1726. PubMed ID: 31149002
    [Abstract] [Full Text] [Related]

  • 17. Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: A novel dual outcome measure in depressive disorders.
    Christensen MC, Loft H, McIntyre RS.
    J Affect Disord; 2018 Feb 01; 227():787-794. PubMed ID: 29689693
    [Abstract] [Full Text] [Related]

  • 18. Cognitive-functional relationships in major depressive disorder: Crucial data from a Ukrainian open-label study of vortioxetine versus escitalopram.
    Levada OA, Troyan AS.
    J Affect Disord; 2019 May 01; 250():114-122. PubMed ID: 30852363
    [Abstract] [Full Text] [Related]

  • 19. Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study.
    Jacobsen PL, Harper L, Chrones L, Chan S, Mahableshwarkar AR.
    Int Clin Psychopharmacol; 2015 Sep 01; 30(5):255-64. PubMed ID: 26020712
    [Abstract] [Full Text] [Related]

  • 20. Head-To-Head Comparison of Vortioxetine Versus Desvenlafaxine in Patients With Major Depressive Disorder With Partial Response to SSRI Therapy: Results of the VIVRE Study.
    McIntyre RS, Florea I, Pedersen MM, Christensen MC.
    J Clin Psychiatry; 2023 May 22; 84(4):. PubMed ID: 37227402
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.